Literature DB >> 28639197

Repurposing CRISPR System for Transcriptional Activation.

Meng Chen1,2, Lei Stanley Qi3,4,5.   

Abstract

In recent years, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has become the most popular one for genome editing. When the nuclease domains of Cas9 protein are mutated into deactivated form (dCas9), CRISPR/dCas9 still retains the ability to bind the targeted DNA sequence, but loses the endonuclease cleavage activity. Taking advantage of the characteristics of this engineered nuclease inactive Cas9, the CRISPR/dCas system has been repurposed into versatile RNA-guided, DNA-targeting platforms, such as genome imaging, gene regulation, and epigenetic modification. Specifically, fusion of dCas9 with activation domains allows specific and efficient transcriptional activation on a genome-wide scale among diverse organisms. The purpose of this chapter is to review most important the recently published literature on CRISPR/dCas9-based transcriptional activation systems. Compared with the conventional approaches for enhancement of the expression of specific genes of interest, CRISPR/Cas9-based system has emerged as a promising technology for genome regulation, allowing specificity, convenience, robustness, and scalability for endogenous gene activation.

Entities:  

Keywords:  CRISPR/Cas; Endogenous gene activation; Gene regulation; Transcriptional activation

Mesh:

Substances:

Year:  2017        PMID: 28639197     DOI: 10.1007/978-981-10-4310-9_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

Review 2.  Genome Editing for Sustainable Agriculture in Africa.

Authors:  Leena Tripathi; Kanwarpal S Dhugga; Valentine O Ntui; Steven Runo; Easter D Syombua; Samwel Muiruri; Zhengyu Wen; Jaindra N Tripathi
Journal:  Front Genome Ed       Date:  2022-05-12

3.  Defining the Teratoma as a Model for Multi-lineage Human Development.

Authors:  Daniella McDonald; Yan Wu; Amir Dailamy; Justin Tat; Udit Parekh; Dongxin Zhao; Michael Hu; Ann Tipps; Kun Zhang; Prashant Mali
Journal:  Cell       Date:  2020-11-04       Impact factor: 41.582

Review 4.  Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.

Authors:  Mohammad Mijanur Rahman; Trygve O Tollefsbol
Journal:  Methods       Date:  2020-04-18       Impact factor: 3.608

5.  Gene activation by a CRISPR-assisted trans enhancer.

Authors:  Xinhui Xu; Jinliang Gao; Wei Dai; Danyang Wang; Jian Wu; Jinke Wang
Journal:  Elife       Date:  2019-04-11       Impact factor: 8.140

Review 6.  Gene surgery: Potential applications for human diseases.

Authors:  Ayman El-Kenawy; Bachir Benarba; Adriana Freitas Neves; Thaise Gonçalves de Araujo; Bee Ling Tan; Adel Gouri
Journal:  EXCLI J       Date:  2019-10-11       Impact factor: 4.068

Review 7.  Control of Bacterial Diseases of Banana Using CRISPR/Cas-Based Gene Editing.

Authors:  Leena Tripathi; Valentine O Ntui; Jaindra N Tripathi
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

8.  Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells.

Authors:  Qizhao Wang; Pei Zhuang; Haoliang Huang; Liang Li; Liang Liu; Hannah C Webber; Roopa Dalal; Leonard Siew; Clarisse M Fligor; Kun-Che Chang; Michael Nahmou; Alexander Kreymerman; Yang Sun; Jason S Meyer; Jeffrey Louis Goldberg; Yang Hu
Journal:  J Neurosci       Date:  2020-04-16       Impact factor: 6.167

Review 9.  CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer.

Authors:  Sushmaa Chandralekha Selvakumar; K Auxzilia Preethi; Kehinde Ross; Deusdedit Tusubira; Mohd Wajid Ali Khan; Panagal Mani; Tentu Nageswara Rao; Durairaj Sekar
Journal:  Mol Cancer       Date:  2022-03-24       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.